Basel Medical Closes $7.98 Million Direct Offering in October
Key Facts
Basel Medical Group closed a registered direct offering on October 9, 2026, in which it sold 6,000,000 units for gross proceeds of $7.98 million, according to a company filing with the U.S. Securities and Exchange Commission. The company said the public offering price was $1.33 per unit and that each unit consisted of one ordinary share and one ordinary warrant to purchase one share. The announcement gives the deal proceeds before commissions and expenses, while the company estimated net proceeds at approximately $7.28 million. It said the funds would be used for working capital, mergers and acquisitions, and other general corporate purposes. The offering closed in October, although the news item covering it is dated November 15.
The offering terms show that the units were sold for $1.33 each, while the company's stock closed at $3.28 on Nasdaq on October 7, according to the final prospectus. The stated unit price was below the stock's closing price that day, two days before the offering closed. Each ordinary warrant entitles its holder to purchase one share and may be exercised immediately upon issuance at a price equal to 110% of the unit price. The warrants remain exercisable for five years from their issuance date, according to the company announcement. The company did not issue pre-funded warrants and said the ordinary warrants are not listed or traded on any exchange.
The warrant terms include a cashless exercise option that could result in the issuance of 6,000,000 additional shares without a cash payment to the company; the company said it does not expect to receive additional funds upon such exercise. The offering increased the number of outstanding ordinary shares from 1,582,111 before its completion to 7,582,111 afterward, with 6,000,000 ordinary warrants outstanding. The deal therefore combines cash proceeds for the company with the possibility of issuing more shares upon warrant exercise, which could increase the number of shares outstanding. The company appointed Cathay Securities as the offering's exclusive agent. The company, its officers and directors, and certain shareholders also entered into 180-day lock-up agreements from the closing date.
The company said in its announcement that restrictions on financing and capital raising apply during the 180-day lock-up period unless it obtains the offering agent's prior written consent. In its annual report, it said it received net proceeds of approximately $7.42 million on October 14, following an initial estimate of approximately $7.28 million when it announced the closing. It reported using approximately $5.92 million of the proceeds for working capital, mergers and acquisitions, and general corporate purposes by the date of the annual report. These later figures provide an account of the funds the company said it received and used after completing the offering. Basel Medical Group describes itself as a Singapore-based medical services provider whose services include orthopedics, trauma, sports medicine, neurosurgery, rehabilitation, and other medical services.
The company's revenue rose approximately 45.2% in the fiscal year ended June 30, 2026, to 16,441,770 Singapore dollars from 11,319,944 Singapore dollars in the prior year. The company attributed the increase to higher activity and demand for the group's services. This annual operating performance provides context for the company's statement that it would direct part of the offering proceeds to working capital and potential mergers and acquisitions. The prospectus also stated that the warrants provide a zero-cash exercise option, which could increase the number of shares available for issuance without a corresponding cash payment to the company. The prospectus warned that the company cannot guarantee that its shares will continue to meet Nasdaq listing requirements.